# Mitsubishi Chemical Holdings Corporation **Condensed Consolidated Financial Information** for the First Half of the Fiscal Year Ending March 31, 2012



1. Business Results for the First Half of the Fiscal Year Ending March 31, 2012 (Business period: April 1, 2011 to September 30, 2011)

(Business period. April 1, 2011 to Septemi	Der 30, 2011)		
	Millions	of Yen	Thousands of
	The First half of	U.S. Dollars The First Half of	
		The First Half of the Previous Fiscal Year	the Current Fiscal Year
	April 1, 2011 -	April 1, 2010 -	April 1, 2011 -
	September 30, 2011	September 30, 2010	September 30, 2011
(1) Results of Operations:		1	
Net sales	1,570,197	1,564,658	20,392,169
Operating income	95,686	111,393	1,242,675
Income before income taxes and minority interests in consolidated subsidiaries	83,369	93,889	1,082,714
Net income	37,504	43,976	487,065
Comprehensive income	60,429	40,465	784,792
		(Von)	(U.S. Dollars
Net income-Basic per share	25.43	(Yen) 32.04	0.33
Net income-Diluted per share	23.52	29.48	0.31
	•		
(2) Segment Information:			
[Net Sales by Segment]	T	1	
Electronics Applications	69,831	80,561	906,896
Designed Materials	338,526	326,837	4,396,442
Health Care	246,717	251,818	3,204,117
Chemicals	466,166	435,249	6,054,104
Polymers	351,964	362,730	4,570,961
Others	96,993	107,463	1,259,649
Total	1,570,197	1,564,658	20,392,169
[Operating Income (loss) by Segment]			
Electronics Applications	(1,179)	3,247	(15,312
Designed Materials	17,335	20,815	225,130
Health Care	· · · · · · · · · · · · · · · · · · ·		
	39,703	44,623	515,623
Chemicals	19,382	21,891	251,714
Polymers	23,295	24,288	302,532
Others Adjustments	1,621	597	21,052
Total	(4,471) 95,686	(4,068) 111,393	(58,065 1,242,675
Total	93,000	111,595	1,242,073
	Millions of Yen		Thousands of U.S. Dollars
	The First Half of	The Previous Fiscal Year	The First Half of
	the Current Fiscal Year September 30, 2011	Ended March 31,2011 March 31, 2011	the Current Fiscal Year September 30, 2011
(3) Financial Position:	September 30, 2011	iviai CH 3 1, ZUTI	September 30, 2011
Total assets	3,255,926	3,294,014	42,284,753
Inventories	543,570	485,061	7,059,351
Property, plant and equipment	1,063,499	1,088,369	13,811,675
Short-term and long-term debt	1,233,145	1,304,589	16,014,870
	-,,	.,55.,566	. 5,5,57 0

<sup>\*</sup>Represents the sum of total shareholders' equity and total accumulated other comprehensive income.

793,447

24.3

Shareholders' equity\*

Ratio of shareholders' equity to total assets (%)

10,304,506

758,247

Millions of Yen			
The First Half of The First Half of			
the Current Fiscal Year   the Previous Fiscal Y			
April 1, 2011 -	April 1, 2010 -		
<b>September 30, 2011</b> September 30, 201			

Thousands of
U.S. Dollars
The First Half of
the Current Fiscal Year
April 1, 2011 -
September 30, 2011

# (4) Cash Flows:

Net cash provided by operating activities	89,573	144,078
Net cash (used in) provided by investing activities	(12,966)	(70,712)
Net cash provided by (used in) financing activities	(83,858)	(62,385)
Cash and cash equivalents at end of the period	138,695	117,245

1,163,286
(168,390)
(1,089,065)
1,801,234

# (5) Ratio of Net Income to:

(	%	)
١		,

Shareholders' equity**	4.8	6.4
Total assets**	1.1	1.3
Net sales	2.3	2.8

<sup>\*\*</sup> Based on the average of the beginning and ending balances of the respective periods.

#### Notes:

The Company and its domestic consolidated subsidiaries maintain their accounting recorded in Japanese yen. The U.S. dollar amounts are included solely for convenience and have been translated, as a matter of arithmetical computation only, at the rate of 77 yen to US\$1, the approximate exchange rate prevailing in the Tokyo foreign exchange market at the end of September 2011.

#### 2. Revised Forecast for the Current Fiscal Year

	Millions of Yen	Thousands of U.S. Dollars
	April 1, 2011 - March 31, 2012	April 1, 2011 - March 31, 2012
Net sales	3,350,000	43,506,494
Operating income	200,000	2,597,403
Net income	77,000	1,000,000
	(Yen)	(U.S. dollar)
Net income per share	52.22	0.68

#### 3. Business Performance and Financial Position

#### (1) Business Performance

Consolidated Performance for the First Half of the Fiscal Year Ending March 31, 2012 (fiscal 2011): Six months ended September 30, 2011

#### **Overview of General Performance**

In the first half of fiscal 2011, the Japanese economy still faced severe conditions due to the effects of the Great East Japan Earthquake. However, some signs of recovery were seen, such as progress in rebuilding the supply chain and an upward trend in individual consumption.

Regarding business environment in the Mitsubishi Chemical Holdings Group, severe environment continued in the Performance Products and Industrial Materials domains due to the effects of the Great East Japan Earthquake, the continued strengthening of the yen and growing concerns at the downward trend in overseas economies as well as the continuing high prices of raw materials and fuel prices. On the other hand, environment in the Health Care domain was generally favorable due to steady performance of demand amid ongoing trend of medical spending constraint despite the influence of the earthquake.

Under the circumstances, the consolidated results for the first half of fiscal 2011 were as follows. Net sales slightly increased by  $\pm 5.5$  billion, or 0.4%, to  $\pm 1,570.2$  billion compared to the same period of fiscal 2010. Operating income deceased by  $\pm 15.7$  billion, or 14.1%, to  $\pm 95.7$  billion compared to the same period of fiscal 2010. Ordinary income decreased by  $\pm 13.5$  billion, or 12.7%, to  $\pm 92.9$  billion compared to the same period of fiscal 2010. Net income decreased by  $\pm 6.5$  billion, or 14.7%, to  $\pm 37.5$  billion compared to the same period of fiscal 2010.

#### (2) Overview of Business Segments

Note: In the following section, all comparisons are with the same period of the previous fiscal year unless stated otherwise.

# <u>Electronics Applications Segment, Performance Products Domain</u> (Recording media, Information and electronics-related materials, Imaging supplies)

Net sales in this segment decreased by ¥10.8 billion, or 13.3%, to ¥69.8 billion. Operating income decreased by ¥4.4 billion, and posted a loss of ¥1.2 billion.

In recording media, net sales drastically decreased due to lower sales volumes in DVDs and external hard disk drives and lowering prices, despite increased sales volumes of flash memory

devices. In information and electronics-related materials, net sales significantly decreased due to a decrease in sales volumes in display materials. In imaging supplies, net sales decreased due to the appreciation of the yen, despite steady sales performance in OPC drums, toners and chemicals toners.

Major initiatives in the Electronics Applications segment during the first half of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced that its subsidiary Mitsubishi Kagaku Media Co., Ltd. and Verbatim Group launched sample kits of VELVE the world's first color-tunable dimming-type OLED panel in Europe, North America, Japan, and the Asia Pacific, and a light source module would be launched in July. (April)
- Mitsubishi Chemical Corporation and Pioneer Corporation jointly developed an optimized wet process that results in an efficiency of 52 lm/W at 1,000 cd/m² in white emission, and a half-life of 20,000 hours with the initial brightness at 1,000 cd/m². These two performance characteristics are, as far as we know, the best in the world. (May)
- Mitsubishi Kagaku Media Co., Ltd. announced the introduction of four LED bulb products to the Japanese market under the Verbatim brand in July. The bulbs allow selection of brightness from three pre-set levels without using a dimmer. (June)
- Verbatim Americas, LLC, a subsidiary of Mitsubishi Kagaku Media Co., Ltd., which was sued
  for trademark infringement in Brazil, made a special appeal to the Superior Court of Justice in
  Brasilia, asking for a judgment on the matter. In June 2011, the Superior Court of Justice in
  Brasilia made the decision to dismiss the trademark-infringement suit and also to dismiss a
  suit from the plaintiff to assess the amount of damages, which were unjustifiably awarded by a
  lower court. (June)

# **Designed Materials Segment, Performance Products Domain**

(Food ingredients, Battery materials, Fine chemicals, Polymer processing products, Composite materials, Inorganic chemicals, Fibers)

Net sales in this segment increased by ¥11.7 billion, or 3.6%, to ¥338.5 billion. Operating income decreased by ¥3.5 billion, or 16.7%, to ¥17.3 billion.

In food ingredients, business generally continued favorably. In battery materials, net sales significantly increased due to a gradual recovery in demand and substitute demand caused by the earthquake, despite lower sales pricing. In fine chemicals, net sales decreased due to a decrease in sales volumes. In polymer processing products, net sales remained unchanged due to a substantial decrease in sales volumes of polyester films and others for flat panel displays, in spite of an increase in sales volumes in engineering plastic products. In composite materials, net

sales of industrial materials such as carbon fibers significantly increased due to continued favorable demand. In inorganic chemicals, net sales drastically decreased due to a decrease in sales volumes by the earthquake. In fibers, net sales increased due to an increase in sales volumes.

Major initiatives in the Designed Materials segment during the first half of fiscal 2011 included:

- MRC-SGL Precursor Co., Ltd., a joint venture of Mitsubishi Rayon Co., Ltd. and the SGL Group, successfully started commercial production of PAN-based precursor, at Otake Japan, one of Mitsubishi Rayon's main manufacturing sites. (MRC-SGL Precursor plans to expand its capacity to 7,000t/y within three years.) (April)
- Mitsubishi Plastics, Inc. announced an expansion of its production facility for alumina fiber MAFTEC at the Sakaide Plant. (Current capacity: 4,800t/y; capacity increase: 800t/y) (April)
- Mitsubishi Rayon Cleansui Co., Ltd., a Mitsubishi Rayon Group company that markets water purification equipment and medical-use water treatment systems, launched sales of *Cleansui* household water purifiers in Australia and New Zealand, through the extensive sales network of Verbatim Corporation, a subsidiary of Mitsubishi Kagaku Media Co., Ltd. that develops, manufactures and markets recording media products, in May. (May)
- Mitsubishi Chemical Corporation and Stella Chemifa Corporation reached an agreement to start studies on business tie-ups, including the establishment of production facilities for electrolytes, main raw materials for electrolytes solution used in lithium-ion batteries in Europe and the US. (June)
- Mitsubishi Rayon Co., Ltd. and its Group company, Nippon Rensui Co., Ltd. concluded a
  memorandum with Singapore's national water agency, PUB on the joint development of
  energy-saving water reclamation technology using the membrane bioreactor method. (July)
- Mitsubishi Rayon Co., Ltd. concluded an agreement with Beijing Origin Water Technology Co., Ltd. to establish a joint venture to manufacture and market hollow fiber membrane for industrial water purification and treatment and to market the membrane bio-reactors (MBRs) system in China. (July)
- Mitsubishi Chemical Corporation announced to expand a production facility of sugar ester at its Yokkaichi Plant. (Current capacity of total food emulsifiers including sugar ester: 10,800t/y; capacity increase: 2,000t/y.) (August)
- Mitsubishi Plastics, Inc. resolved to expand a production facility of separators for lithium-ion batteries at its Nagahama Plant. (Current capacity: 12 million m²; capacity increase: 15 million m².) (August)
- Mitsubishi Chemical Corporation resolved to establish a subsidiary in China to manufacture and market electrolytes solution for lithium-ion batteries. (Capacity: 10,000t/y.) (September)

### **Health Care Segment, Health Care Domain**

# (Pharmaceuticals, Diagnostic reagents and instruments, Clinical testing)

Net sales in this segment decreased by ¥5.1 billion, or 2.0%, to ¥246.7 billion. Operating income decreased by ¥4.9 billion, or 11.0 %, to ¥39.7 billion, due partly to an increase in SG & A expenses.

In the pharmaceutical business, net sales decreased due to a temporary increase in orders for the last fiscal year by the influence of the earthquake, which inversely affected orders for the first half of fiscal 2011, despite continued favorable sales in Remicade, an anti-TNF $\alpha$  monoclonal antibody; Talion, a treatment for allergic disorders and Maintate, angina pectoris hypertension and arrhythmias. In diagnostic reagents and instruments and clinical testing, net sales remained unchanged.

Major initiatives in the Health Care segment during the first half of fiscal 2011 included:

- Mitsubishi Tanabe Pharma Corporation that the company obtained approval for additional indication for selective ß1 antagonist, *Maintate* (generic name: JP bisoprolol fumarate) for chronic heart failure resulting from ischemic heart disease or dilated cardiomyopathy. (May)
- Mitsubishi Tanabe Pharma Corporation announced that it has launched anti-allergy agent, bepotastine besilate (product name in Japan: *Talion*) in China and Indonesia through its consolidated subsidiaries, Tianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia, respectively. (May)
- Mitsubishi Tanabe Pharma Corporation and the Japanese Red Cross Society announced that
  they have reached an agreement to commence discussions about an integration of Benesis
  Corporation, a subsidiary of Mitsubishi Tanabe Pharma and Japan Red Cross Society's
  plasma fractionation operations. (June)
- The Asikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd., a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation, received a 10-day suspension order for manufacturing of pharmaceuticals from Tochigi Prefecture because of failure to perform certain quality assurance tests related to the shipping of products. Furthermore, Mitsubishi Tanabe Pharma received a business improvement order from the Minister of Health, Labour and Welfare. (July)
- Mitsubishi Tanabe Pharma Corporation and Mochida Pharmaceutical Co., Ltd. announced that Lexapro 10mg, for which Mochida obtained the marketing approval, has been jointly launched.
   (August)
- Mitsubishi Tanabe Pharma Corporation announced that the company has received approval for a partial change of dosage and usage in Crohn's disease for an anti-human TNF-  $\alpha$  monoclonal-antibody, *Remicade* for I.V. Infusion 100. (August)

- Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. jointly launched a human TNF-α monoclonal antibody, SIMPONI Subcutaneous Injection 50mg Syringe, for the treatment of rheumatoid arthritis. It was jointly developed by Mitsubishi Tanabe Pharma and Janssen Pharmaceutical, and in July, Janssen Pharmaceutical obtained the manufacturing and marketing license. (September)
- Mitsubishi Tanabe Pharma Corporation announced that the company has received approval for the manufacturing and marketing of *TELAVIC* 250mg Tablet, an antiviral chronic hepatitis C. (September)
- Mitsubishi Tanabe Pharma Corporation announced that the company obtained the manufacturing and marketing approval for *IMUSERA* Capsules 0.5mg for the indication of prevention of relapse and delay of progression of physical disability in multiple sclerosis. (September)

#### **Chemicals Segment, Industrial Materials Domain**

(Basic petrochemicals, Chemical derivatives, Synthetic fiber materials, Carbon products)

Net sales in this segment increased by ¥30.9 billion, or 7.1%, to ¥466.2 billion. Operating income decreased by ¥2.5 billion, or 11.5%, to ¥19.4 billion partly due to the influence of the earthquake and a shrunk price variance between coking coal and blast furnace coke, in spite of an improvement in price variance between raw material and product in terephthalic acid.

The production volume of ethylene, a basic raw material of petrochemicals, decreased by 28.9% to 401 thousand tons primarily due to the ethylene production facilities at the Kashima Plant of Mitsubishi Chemical Corporation that stopped operations in the wake of the earthquake, compared to the same period of fiscal 2010. In basic petrochemicals, chemical derivatives, net sales drastically decreased due to a significant decrease in sales volumes by the influence of the earthquake, despite a sales price adjustment along with an increase in raw materials. In synthetic fiber materials, net sales considerably increased due primarily to a substantial upward trend in terephthalic acid market. In carbon products, net sales of blast furnace coke significantly increased due primarily to an increase in coking coal price.

Major initiatives in the Chemicals segment during the first half of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced that the Kashima No. 2 ethylene production facility stopped operations in the wake of the earthquake restarted on May 20, and the Kashima No. 1 ethylene production facility stopped in the same way restarted on June 30 after regular maintenance. (May and June)
- Mitsubishi Chemical Corporation entered into an agreement on basic policies to establish a
  joint venture in South Korea to manufacture and market needle coke with Posco Group and

Mitsubishi Corporation (capacity: approximately 60,000t/y). Based on this agreement, Mitsubishi Chemical plans to strengthen stable supply of raw material for its carbon business by receiving raw material, tar from Posco Group. (September)

# <u>Polymers Segment, Industrial Materials Domain</u> (Synthetic resins)

Net sales in this segment decreased by ¥10.7 billion, or 3.0%, to ¥352.0 billion. Operating income decreased by ¥1.0 billion, or 4.1%, to ¥23.3 billion due to a decrease in sales volumes in acrylic resin and polyolefin and others, as well as slumping export prices..

In synthetic resins, net sales decreased due to a decrease in sales volumes in acrylic resin along with a decreased demand in light guiding panel and a significant decrease in sale volumes in polyolefin and others by the influence of the earthquake, despite an increase in sales volumes along with a substantial upward trend in market price of MMA monomer.

Major initiatives in the Polymers segment during the first half of fiscal 2011 included:

- Mitsubishi Chemical Corporation announced establishment of a joint venture with PTT Public Company Limited to accelerate global expansion of GS Pla, a biodegradable plastic. (April)
- Mitsubishi Chemical Corporation announced conclusion of an agreement on business partnerships with BioAmber Inc. and Mitsui & Co., Ltd. which has interest in BioAmber. The partnership is to be concentrated on supplying biomass succinic acid, conducting R&D, and production technologies for the biomass biodegradable plastic, GS Pla. (April)
- Mitsubishi Chemical Corporation and Genomatica, Inc. concluded an agreement to jointly develop production technologies to produce chemicals such as 1,4-butanediol from biomass resources. (April)
- Mitsubishi Chemical Corporation announced an increase in PVC compound production capacity in Thailand. (Current capacity: 15,000t/y; capacity increase: 4,000t/y) (May)
- Mitsubishi Chemical Corporation announced establishment of a new production facility for olefin thermoplastic elastomer and adhesive polymer in China (capacity: 4,500t/y), and to expand a production facility for olefin thermoplastic elastomer and adhesive polymer in North America (Current capacity: 9,200t/y; capacity increase: 1,900t/y). (May)
- Mitsubishi Rayon Co., Ltd. and Saudi Basic Industries Corporation (SABIC) announced conclusion of an agreement aiming to the formation of a joint venture company to build and operate two plants one for methyl methacrylate (MMA; capacity: 250,000t/y) and the other for polymethylmethacrylate (PMMA; capacity: 40,000t/y) at one of SABIC's manufacturing affiliates in Jubail, Saudi Arabia. (May)
- · Mitsubishi Rayon Co., Ltd. resolved to launch production of 2-hydroxyethyl methacrylate

(2HEMA) (capacity: 11,000t/y) at Daesan MMA Corp. of South Korea, a joint venture set up with Honam Petrochemial Corp. (September)

#### **Others**

## (Engineering, Logistics)

Net sales in this segment decreased by ¥10.5 billion, or 9.7%, to ¥97.0 billion. Operating income increased by ¥1.0 billion, or 171.5%, to ¥1.6 billion.

In engineering, the business continued favorably. In logistics, net sales decreased due to the influence of the earthquake. Other than these, net sales in other businesses decreased due primarily to termination of some purchase and resale business.

#### **Group in General**

Major initiatives in the Group in general other than the above-mentioned segments during the first half of fiscal 2011 included:

• Mitsubishi Chemical Holdings Corporation resolved to relocate the Mitsubishi Chemical Holdings Group headquarters to a new location from May to August 2012. Mitsubishi Chemical Holdings, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Inc., and Mitsubishi Rayon Co., Ltd., which are all in Tokyo, will move to a single headquarters office building and a part of the offices of Mitsubishi Tanabe Pharma Corporation, which is headquartered in Tokyo and Osaka, will move to the new headquarters as well. (August)

#### 4. Consolidated Financial Position

At the end of the first half of fiscal 2011, total assets amounted to ¥3,255.9 billion, a decrease of ¥38.1 billion compared to the end of fiscal 2010. This reflected a decrease in investment securities caused by a decline in market value of shares held and a decrease in cash and deposits and securities used to reduce interest-bearing debts, while inventories increased due to the rise in raw material and fuel prices.

#### 5. Consolidated Financial Results Forecasts for Fiscal 2011

The consolidated financial results forecasts for fiscal 2011 announced on August 1, 2011 have been revised downward in light of the results of the first half of fiscal 2011. This was due primarily to a decrease in demand in flat panel display related products and weakening market for petrochemicals, as well as continued strengthening of the yen which exceeds expectations.

# 1) Revised consolidated financial results forecasts for fiscal 2011

(Units are in billions of yen, otherwise noted.)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecasts (A) (announced on August 1, 2011)	3,490.000	221.000	220.000	90.000	61.04 yen
Revised forecasts (B)	3,350.000	200.000	195.000	77.000	52.22 yen
Difference (B-A)	(140.000)	(21.000)	(25.000)	(13.000)	-
Difference (%)	(4.0)	(9.5)	(11.4)	(14.4)	-
Reference: Results for fiscal 2010	3,166.771	226.493	223.899	83.581	58.72 yen

# **Forward-looking Statements**

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond company control. Actual results could differ materially due to numerous factors, including without limitation market conditions, and the effect of industry competition. The company expectations for the forward-looking statements are described in page [2], [9] and [10] hereof.